---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-030051"
form_type: "8-K"
ticker: "BIXT"
cik: "0001445815"
company_name: "BIOXYTRAN, INC"
filed_at: "2023-08-24T23:59:59+00:00"
generated_at: "2026-06-11T04:05:42.790414+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bioxytran receives FDA clearance to initiate clinical trials for ProLectin-M in COVID-19

## Summary
- FDA cleared IND No. 153742 for ProLectin-M, an oral galectin antagonist for mild-to-moderate COVID-19.
- ProLectin-M is Bioxytran's first program to enter the clinic; it aims to showcase broad-spectrum antiviral potential.
- Prior phase 2 trial showed 100% PCR-negative by day 7 and 88% by day 3; no viral rebounds.
- Company preparing for Phase 3 to seek regulatory approval of ProLectin-M.

## SEC filing metadata
- accession: 0001493152-23-030051
- form_type: 8-K
- ticker: BIXT
- cik: 0001445815
- company_name: BIOXYTRAN, INC
- filed_at: 2023-08-24T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445815/000149315223030051/0001493152-23-030051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445815/000149315223030051/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-030051
- JSON: https://secwatch.observer/filing/0001493152-23-030051.json
- Plain text: https://secwatch.observer/filing/0001493152-23-030051.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.